PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer

Clicks: 208
ID: 274468
2006
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #73 of 239 articles by views in Oncogene

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 239 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide p …
Reference Key
dj2006oncogenepten Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mulholland DJ;Dedhar S;Wu H;Nelson CC;;
Journal Oncogene
Year 2006
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16421604
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine male disease progression androgens / physiology* pmid:16421604 doi:10.1038/sj.onc.1209020 d j mulholland s dedhar c c nelson glycogen synthase kinase 3 / physiology* glycogen synthase kinase 3 beta pten phosphohydrolase / physiology* prostatic neoplasms / physiopathology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.